Sorafenib is an oral multi-kinase inhibitor that suppresses tumor cell production by aiming Raf/MEK/ERK signaling at the level of Raf kinase and utilizes an antiangiogenic influence by aiming vascular endothelial development factor receptor -2/-3(VEGFR-2/-3), and platelet-derived growth factor receptor beta (PDGFR-) tyrosine kinases (22). This evidence concerns the gene KDR and neoplasm.